[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy-abnormal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy-abnormal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100354845","french-registry-for-monitoring-pregnancies-for-multiple-sclerosis-100354845",false,"NCT03900221","French Registry for Monitoring Pregnancies for Multiple Sclerosis","French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort","RESPONSE","Inclusion Criteria:\n\n* All groups of patients eligible to participate to the Observatoire Français de la Sclérose en Plaque (OFSEP), including :\n* Definite Multiple sclerosis (MS) according to McDonald criteria\n* Whatever the clinical course (single attack MS, relapsing-remitting MS, secondary progressive MS, primary progressive MS)\n* Radiologically Isolated Syndromes (RIS) (will be validated by the RIS expert group)\n* Clinically Isolated Syndromes (CIS)\n* Neuromyelitis optica (NMO) and NMO spectrum disorders (will be validated by the \"Neuro-optico-myélite aiguë de Devic et des syndromes neurologiques apparentés\" (NOMADMUS) expert group)\n* No age limit (patients under the age of 18 might be included, provided informed consent is obtained from the parents)\n* Ongoing pregnancy: there will be no limit in the gestational age at inclusion. Women can be included at any time before delivery, but the gestational age at inclusion will be recorded and introduced in the analyses whenever pertinent. However, neurologists and patients will be encouraged to start the study as soon as pregnancy is diagnosed.\n* Able to give informed consent\n* Able to read and\u002For understand French\n\nExclusion Criteria:\n\n* None","ALL",{"count":19,"type":20},1500,"ESTIMATED","7 Years","OBSERVATIONAL","The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire of motherhood. However, there are still some challenges for the neurologist, who has to face old unanswered questions or new issues, regarding the use of disease modifying drugs (DMDs) in this period of life, effects on the short and long term outcome of the mother (in terms of relapses and disability) and the child, role of breast-feeding and locoregional analgesia.\n\nTo set up a national prospective pregnancy registry for patients with MS, nested within the Observatoire Français de la Sclérose en Plaque (OFSEP) cohort, owing to a better knowledge of interactions between MS and pregnancy-related issues (pregnancy itself, locoregional analgesia, breastfeeding, impact of using or stopping DMDs on women\u002Fchildren…)",[25,26,27,28],"Sclerosis, Multiple","Neuromyelitis Optica Spectrum Disorder","Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders","Pregnancy Abnormal",[30,31,32,33,34],"Multiple sclerosis","pregnancy","disease modifying drugs","breastfeeding","loco-regional analgesia","RECRUITING","2025-12-30",{"date":38,"type":39},"2026-01-05","ACTUAL",{"date":41,"type":39},"2019-08-12",{"date":43,"type":20},"2036-08-12",{"name":45,"class":46},"Hospices Civils de Lyon","OTHER",48,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100606095","phase-4-ai-pocus-for-maternal-and-neonatal-health-in-ethiopia-100606095","NCT07171086","AI-POCUS for Maternal and Neonatal Health in Ethiopia","AI-POCUS to Improve Maternal and Neonatal Health Outcomes in Rural Ethiopia: A Three-Arm Cluster Randomized Controlled Trial","AIM-ETH","Inclusion Criteria:\n\n1. Aged 15-49 years;\n2. Gestational age less than 24 weeks at the first ANC visit;\n3. No history of severe pregnancy complications (e.g., placenta previa, preeclampsia, etc.);\n4. Signed informed consent and agreed to participate in the study.\n\nExclusion Criteria:\n\n1. Pregnant women with cognitive impairments or unable to communicate effectively;\n2. Failure to complete antenatal care within the specified timeframe;\n3. Incomplete or unavailable records of antenatal care and delivery.",true,"FEMALE","15 Years","49 Years",{"count":61,"type":20},1059,"INTERVENTIONAL",[64],"PHASE4","Maternal and neonatal health remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Ethiopia continues to face a high burden, with maternal mortality estimated at 195 per 100,000 live births, neonatal mortality at 27 per 1,000 live births, and perinatal mortality rates ranging from 37‰ to 124‰ depending on the level of care. These outcomes remain substantially higher than the targets set under the United Nations Sustainable Development Goals (SDGs) for 2030.\n\nThe World Health Organization (WHO) recommends that all pregnant women receive at least one ultrasound scan before 24 weeks of gestation, yet nearly two-thirds of women worldwide-especially in LMICs-lack access to this service. Barriers include high costs of ultrasound machines, limited technical expertise, and shortages of skilled sonographers in rural primary care.\n\nArtificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) represents a promising innovation to expand prenatal imaging in resource-constrained settings by equipping frontline health workers with AI-supported diagnostic capabilities. This study, conducted under the Tsinghua University BRIGHT (Bringing Research to Impact for Global Health at Tsinghua) program, will evaluate the clinical effectiveness, feasibility, cost, and scalability of AI-POCUS in rural Ethiopia. A three-arm cluster randomized controlled trial will compare two AI-enabled ultrasound technologies-BabyChecker (Netherlands) and a China-developed AI-POCUS device-against standard antenatal care without ultrasound. Findings will generate robust clinical and policy-relevant evidence to guide the sustainable implementation of AI-enabled maternal health interventions in sub-Saharan Africa.",[67,68,69,70,71,28],"Pregnancy","Pregnancy Complications","Preterm Birth","Fetal Growth Restriction","Stillbirth and Fetal Death",[73,74,75,76,77,78],"Artificial Intelligence","Point-of-Care Ultrasound (POCUS)","Maternal and Neonatal Health","Cluster Randomized Controlled Trial","Sub-Saharan Africa","Rural Centers","NOT_YET_RECRUITING","2025-09-05",{"date":82,"type":39},"2025-09-12",{"date":84,"type":20},"2025-09-30",{"date":86,"type":20},"2026-08-31",{"name":88,"class":46},"Tsinghua University",1]